Sep 21, 2022Anavex Life Sciences new U.S. Patent ANAVEX®2-73 (blarcamesine) for Neurodevelopmental Disorders
Aug 23, 2022Anavex Reports Publication in Medical Journal Highlighting the Relevance of SIGMAR1 Activation in AD
Aug 2, 2022Long-lasting Effect of ANAVEX®3-71 Prevents Cognitive Decline in Animal Model of AD at AAIC 2022
Jul 31, 2022Anavex Announces First Entire Clinical Alzheimer’s Gene Pathway Data of ANAVEX®2-73 at AAIC 2022
